Eli Lilly and Company ($LLY) Stock Forecast: Up 8.4% Today

What is Eli Lilly and Company?

Eli Lilly and Company (NYSE: LLY) is a pharmaceutical company known for its innovative medicines in various therapeutic areas. The stock had a strong bullish movement today amidst positive market sentiment.

Why is Eli Lilly and Company going up?

LLY stock is up 8.4% on Oct 1, 2025 19:36

• Eli Lilly's stock surged due to an announcement by President Donald Trump regarding a deal with Pfizer, which included the 'TrumpRx' platform aimed at reducing drug prices. This news boosted investor confidence in the pharmaceutical sector.
• The partnership between Pfizer and Washington had a significant impact on the industry, leading to companies like Eli Lilly benefiting from the positive market sentiment.
• Furthermore, bullish bets from high-net-worth investors, as reflected in publicly available options history, added to the upward momentum in Eli Lilly's stock.
• The overall optimism surrounding Eli Lilly, along with strategic expansions and favorable analyst recommendations, played key roles in the stock's impressive performance on the day.

LLY Price Chart

LLY Technical Analysis

LLY News

Eli Lilly Shares Are Trading Higher Wednesday: What's Going On? - Eli Lilly ( NYSE:LLY )

Eli Lilly And Company ( NYSE:LLY ) shares are trading higher Wednesday after President Donald Trump recently announced a deal with Pfizer as well as the 'TrumpRx' site to decrease prices. What To Know: Pfizer agreed to provide medicines on the TrumpRx platform at steep discounts and extend ...

https://www.benzinga.com/trading-ideas/movers/25/10/47980051/eli-lilly-shares-are-trading-higher-wednesday-whats-going-on

Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away - CVS Health ( NYSE:CVS ) , Eli Lilly ( NYSE:LLY ) , Pfizer ( NYSE:PFE ) , UnitedHealth Group ( NYSE:UNH )

Pfizer Inc's ( NYSE:PFE ) deal with Washington isn't just a handshake in the Oval Office - it's a seismic jolt to America's drug-pricing game.

https://www.benzinga.com/trading-ideas/long-ideas/25/10/47971458/pfizers-trumprx-pact-sends-shockwaves-why-unitedhealth-lilly-and-cvs-cant-look-away

Can NVO Maintain Obesity Leadership With Next-Generation Candidates?

Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.

https://www.zacks.com/stock/news/2759711/can-nvo-maintain-obesity-leadership-with-next-generation-candidates

Is Lilly ( LLY ) a Buy as Wall Street Analysts Look Optimistic?

The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

https://www.zacks.com/stock/news/2759563/is-lilly-lly-a-buy-as-wall-street-analysts-look-optimistic

This Is What Whales Are Betting On Eli Lilly - Eli Lilly ( NYSE:LLY )

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly ( NYSE: LLY ) . We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

https://www.benzinga.com/insights/options/25/09/47916750/this-is-what-whales-are-betting-on-eli-lilly

Trending Today

Duolingo Inc. ($DUOL) Stock Forecast: Down 6.9% Today

Centene Corporation ($CNC) Stock Forecast: Up 12.8% Today

American Electric Power Company Inc. ($AEP) Stock Forecast: Up 6.2% Today

DaVita Inc. ($DVA) Stock Forecast: Down 1.9% Today

Garmin Ltd. ($GRMN) Stock Forecast: Down 11.7% Today

Fiserv Inc. ($FI) Stock Forecast: Down 43.9% Today

PayPal Holdings Inc. ($PYPL) Stock Forecast: Down 5.3% Today

Caterpillar Inc. ($CAT) Stock Forecast: Up 11.6% Today

Innovative Industrial Properties Inc ($IIPR) Stock Forecast: Down 5.6% Today

Robert Half Inc. ($RHI) Stock Forecast: Down 5.2% Today

Eli Lilly and Company Price History

15.07.2025 - LLY Stock was up 5.1%

• Eli Lilly stock climbed significantly today, driven by several factors:
• The UK monthly price increase for Mounjaro's highest dose and the pricing adjustment in India's Mounjaro Kwikpen likely contributed to the positive movement.
• Insider moves within the company, such as bold buys and record sales, may have boosted investor confidence.
• Speculation around undervalued healthcare stocks, including Eli Lilly, could have attracted buyers looking for potential growth opportunities.

26.07.2025 - LLY Stock was up 5.0%

• Eli Lilly stock surged after positive results from its oral GLP-1 pill trial, which demonstrated impressive weight loss benefits and blood sugar level reductions.
• The success of the weight-loss pill trial has fueled investor optimism and confidence in Eli Lilly's future growth prospects.
• Despite a setback with its orforglipron pill, the company's robust late-stage pipeline continues to support expectations for sustained growth and innovation in the pharmaceutical sector.
• The investigation by the Portnoy Law Firm into Eli Lilly's activities does not seem to have impacted the stock's bullish momentum, indicating that investors are primarily focused on the positive trial results and growth potential.

29.06.2025 - LLY Stock was down 5.2%

• The company witnessed a bearish movement in its stock performance.
• Reduced sales growth outlook of a competitor and concerns over illegal weight-loss drug imports impacting a specific drug category may have influenced overall market sentiment towards the company.
• Despite positive news of a drug recommendation for Alzheimer's disease, it may not have fully offset the prevailing negative market sentiment.
• The bearish stance taken by investors through options trading likely contributed to the stock's decline.

29.06.2025 - LLY Stock was down 6.1%

• The decline in Eli Lilly's stock could be linked to investors taking a bearish stance in options trading, as shown by publicly available options history.
• Concerns raised by Congress about the illegal import of weight-loss drugs from China, which also mentioned Eli Lilly, may have further dampened investor sentiment.
• While Eli Lilly received positive news of early Alzheimer's drug approval recommendation in Europe, the market seemed more influenced by general pessimism and regulatory risks.
• The conclusion of the Verve tender offer involving Eli Lilly likely impacted investor sentiment and contributed to the stock's bearish movement.

29.06.2025 - LLY Stock was down 6.7%

• The bearish movement in LLY stock could be attributed to concerns raised by Congress over illegal weight-loss drug imports from China, which might impact the company's reputation and sales.
• Despite the positive news of Eli Lilly's early Alzheimer's drug recommendation for approval in Europe, the market might be reacting more to the potential safety risks associated with illegal drug imports.
• Investors might be cautious about the upcoming Q2 earnings report, especially regarding the performance of Eli Lilly's oncology drugs, as any underperformance could have contributed to the bearish trend.
• The expiration of the Verve tender offer might also be a factor in the stock's movement, signaling potential shifts in the company's strategic partnerships or future developments.

15.06.2025 - LLY Stock was down 1.2%

• Deep-pocketed investors have recently taken a bearish approach towards Eli Lilly (LLY) options, which may have contributed to the stock's significant decline today.
• Despite the positive outlook for LLY's drugs like Mounjaro and Zepbound driving strong revenues, the bearish sentiment from market whales on the options front seems to have overshadowed the company's potential.
• The threat of 200% tariffs on pharmaceutical imports by President Trump could have also added to the overall bearish sentiment in the market, impacting stocks like Eli Lilly.
• While there were some bullish bets on Eli Lilly from other investors, the overall market movement today seems to have been influenced more by the bearish stance taken by market whales and external factors like trade tariffs.

07.07.2025 - LLY Stock was down 13.3%

• Despite surpassing earnings and revenue estimates in Q2, Eli Lilly's stock experienced a bearish movement.
• The disappointment in the weight loss results of Orforglipron compared to financial forecasts may have contributed to the stock's decline.
• Threats of imposing high tariffs on pharmaceutical imports could have added uncertainty to the market, impacting Eli Lilly's stock negatively.
• The reversal of early weakness and the climb of 1.8% towards the end of the day could indicate some resilience in the stock, potentially driven by positive trading signals and smart money inflow.

08.06.2025 - LLY Stock was up 0.2%

• Eli Lilly has showcased impressive performance, outperforming the market substantially over the past decade, attracting investors seeking strong returns.
• Sales growth fueled by non-obesity drugs like Verzenio and Taltz highlights the company's diversified product portfolio and its ability to seize market opportunities across different drug categories.
• Positive sentiments from Wall Street analysts, with most recommending buying the stock, might have bolstered investor confidence in the company's future, contributing to the stock's bullish movement.
• Eli Lilly's robust market performance, promising sales growth, and favorable analyst outlook likely supported the bullish stock movement observed today.

01.09.2025 - LLY Stock was up 11.2%

• Eli Lilly's stock (LLY) has seen a bullish trend, driven by encouraging recommendations from financial analysts on Wall Street, signaling a buy outlook among investors.
• Remarkably, Pfizer's agreement with the Trump administration concerning drug pricing has had a constructive impact on the pharmaceutical industry, including companies like Eli Lilly.
• Investor confidence, potentially from institutions or high-net-worth individuals, in Eli Lilly has intensified the upward trajectory of its stock.
• Additionally, Amgen's enhancement of its U.S. manufacturing footprint amid evolving tariff regulations could have indirectly contributed to the positive market sentiment around pharmaceutical firms like Eli Lilly.

01.09.2025 - LLY Stock was up 8.4%

• Eli Lilly's stock surged due to an announcement by President Donald Trump regarding a deal with Pfizer, which included the 'TrumpRx' platform aimed at reducing drug prices. This news boosted investor confidence in the pharmaceutical sector.
• The partnership between Pfizer and Washington had a significant impact on the industry, leading to companies like Eli Lilly benefiting from the positive market sentiment.
• Furthermore, bullish bets from high-net-worth investors, as reflected in publicly available options history, added to the upward momentum in Eli Lilly's stock.
• The overall optimism surrounding Eli Lilly, along with strategic expansions and favorable analyst recommendations, played key roles in the stock's impressive performance on the day.

17.06.2025 - LLY Stock was down 3.4%

• Eli Lilly's stock (LLY) faced a bearish trend, potentially influenced by concerns regarding its valuation despite a strong performance in the last decade.
• The negative stance taken by significant investors towards LLY options could have contributed to the stock's downward pressure.
• Even though drugs like Mounjaro and Zepbound hold promise for driving robust quarterly earnings, the prevailing market sentiment towards Eli Lilly was mostly unfavorable, resulting in the bearish movement.

30.08.2025 - LLY Stock was up 5.3%

• Eli Lilly (LLY) stock surged due to positive market sentiment and investor confidence in the company's growth prospects.
• The bullish stance taken by investors, including institutions and high-net-worth individuals, further boosted the stock's performance.
• Analysts' optimistic recommendations and the company's strategic position in the pharmaceutical industry also contributed to the bullish movement.
• While competitors like Novo Nordisk, Amgen, and AstraZeneca made headlines, it was Lilly's own positive outlook that drove its stock price higher today.